Literature DB >> 11676305

Postdischarge adverse drug reactions in primary care originating from hospital care in France: a nationwide prospective study.

L Letrilliart1, T Hanslik, M Biour, J P Fagot, M Guiguet, A Flahault.   

Abstract

OBJECTIVE: To describe and estimate the incidence and preventability of postdischarge adverse drug reactions (ADRs) detected in primary care in France.
DESIGN: Prospective study of patients referred to hospital by participating general practitioners (GPs). These GPs reported all cases of an adverse reaction to a drug instituted in hospital among patients who consulted them within 30 days of discharge.
SETTING: 305 general practices from all French regions. PATIENTS: 7540 patients referred by GPs to private or public hospitals. MAIN OUTCOME MEASURES: The incidence for postdischarge ADRs in primary care, and their preventability.
RESULTS: 30 cases of postdischarge ADR were detected in 29 re-consulting patients, yielding a minimal incidence for France of 0.4 per 100 admissions (95% confidence interval 0.3 to 0.6). The ADRs were assessed as serious in 60% of cases. The main drug classes implicated were cardiovascular drugs (8 ADRs), oral anticoagulants (6), psychoactive drugs (4), antidiabetics (3), and opioid analgesics (3). Patients experiencing a postdischarge ADR were older than patients not experiencing one (median age: 77 vs 68 years; p = 0.004). Detected ADRs were considered preventable in 59% of cases.
CONCLUSIONS: Physicians and patients should be aware of the possible occurrence of postdischarge ADRs. Patient information in hospital, close postdischarge follow-up of patients at risk, and appropriate transmission of information between hospital physicians and GPs can help to prevent them.

Entities:  

Mesh:

Year:  2001        PMID: 11676305     DOI: 10.2165/00002018-200124100-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  42 in total

1.  Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.

Authors:  M Fava; J F Rosenbaum; S L Hoog; R G Tepner; J B Kopp; M E Nilsson
Journal:  J Affect Disord       Date:  2000-08       Impact factor: 4.839

2.  Under-reporting of adverse drug reactions in general practice.

Authors:  Y Moride; F Haramburu; A A Requejo; B Bégaud
Journal:  Br J Clin Pharmacol       Date:  1997-02       Impact factor: 4.335

Review 3.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

4.  Intensive monitoring for adverse drug effects in patients discharged from acute medical wards.

Authors:  G S Kellaway; E McCrae
Journal:  N Z Med J       Date:  1973-12-26

5.  Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.

Authors:  M C Perry; W L Eaton; K J Propert; J H Ware; B Zimmer; A P Chahinian; A Skarin; R W Carey; H Kreisman; C Faulkner
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

6.  Frequency and cost of serious adverse drug reactions in a department of general medicine.

Authors:  N Moore; D Lecointre; C Noblet; M Mabille
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

7.  Adverse biochemical and clinical consequences of furosemide administration.

Authors:  M Spino; E M Sellers; H L Kaplan; C Stapleton; S M MacLeod
Journal:  Can Med Assoc J       Date:  1978-06-24       Impact factor: 8.262

8.  Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients.

Authors:  J D Seeger; S X Kong; G T Schumock
Journal:  Pharmacotherapy       Date:  1998 Nov-Dec       Impact factor: 4.705

9.  Predisposing factors in adverse reactions to drugs.

Authors:  N Hurwitz
Journal:  Br Med J       Date:  1969-03-01

10.  United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.

Authors: 
Journal:  BMJ       Date:  1995-01-14
View more
  7 in total

1.  Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department.

Authors:  Pascale Olivier; Olivier Boulbés; Marie Tubery; Dominique Lauque; Jean-Louis Montastruc; Maryse Lapeyre-Mestre
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Methods for assessing the preventability of adverse drug events: a systematic review.

Authors:  Katja Marja Hakkarainen; Karolina Andersson Sundell; Max Petzold; Staffan Hägg
Journal:  Drug Saf       Date:  2012-02-01       Impact factor: 5.606

3.  Drug related problems after discharge from an Australian teaching hospital.

Authors:  Glena R Ellitt; Ellinor Engblom; Parisa Aslani; Tommy Westerlund; Timothy F Chen
Journal:  Pharm World Sci       Date:  2010-06-26

4.  Avoidability of adverse drug reactions spontaneously reported to a French regional drug monitoring centre.

Authors:  Annie Pierre Jonville-Béra; Hassan Saissi; Lamiae Bensouda-Grimaldi; Frederique Beau-Salinas; Haware Cissoko; Bruno Giraudeau; Elisabeth Autret-Leca
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 5.  Epidemiology of adverse drug reactions in Europe: a review of recent observational studies.

Authors:  Jacoline C Bouvy; Marie L De Bruin; Marc A Koopmanschap
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.606

6.  Prevalence and Nature of Medication Errors and Medication-Related Harm Following Discharge from Hospital to Community Settings: A Systematic Review.

Authors:  Fatema A Alqenae; Douglas Steinke; Richard N Keers
Journal:  Drug Saf       Date:  2020-06       Impact factor: 5.606

7.  Adaptation and validation of an adverse drug reaction preventability score for bleeding due to vitamin K antagonists.

Authors:  Sophie Liabeuf; Kamel Masmoudi; Lucie-Marie Scailteux; Julien Moragny; Henri Masson; Valérie Brnet-Dufour; Michel Andrejak; Valérie Gras-Champel
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.